A Phase 2 Single-Blind, Randomized, Controlled, Single Center Study to Assess the Immunogenicity and Safety of a 2-Dose Schedule With GVGH altsonflex1-2-3 Vaccine in African Infants (H06_02TP)
Latest Information Update: 23 Jan 2025
Price :
$35 *
At a glance
- Drugs GSK 4001785A (Primary)
- Indications Shigella infections
- Focus Therapeutic Use
- Sponsors GSK
- 20 Jan 2025 Planned End Date changed from 17 Sep 2025 to 3 Oct 2025.
- 20 Jan 2025 Planned primary completion date changed from 17 Sep 2025 to 3 Oct 2025.
- 20 Jan 2025 Status changed from not yet recruiting to recruiting.